SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SE-7552

Cat. No.:	HY-161305
CAS No.:	2243575-79-1
Molecular Formula:	$C_{15}H_{12}F_3N_5O$
Molecular Weight:	335.28
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (298.26 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.9826 mL	14.9129 mL	29.8258 mL
	5 mM	0.5965 mL	2.9826 mL	5.9652 mL
	10 mM	0.2983 mL	1.4913 mL	2.9826 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (7.46 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.46 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC_{50} of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice[1][2].

IC_{50} & Target

HDAC6
33 nM (IC_{50})

In Vivo

SE-7552 (30 mg/kg; a single oral dose) increases the levels of acetylated α-tubulin for over 24 hours in mice. SE-7552 has no effect on the acetylation of H3 (a biomarker for inhibition of Class I HDACs)[1].
SE-7552 (10 mg/kg; orally; daily) combinated with Pomalidomide (HY-10984; 1 mg/kg; IP daily) significantly delays tumor

growth in comparison to Pomalidomide alone, as well as enhanced the survival of the mice with human H929 MM cells[1]. SE-7552 demonstrated superior PK, with a maximum exposure of 597 ng/ml and a half-life of 7.2 hours after a single oral dose of 5 mg/kg in the mouse[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jason A Holt, et al. SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo. Blood (2018) 132 (Supplement 1): 3215.

[2]. Beate König, et al. 2-(Difluoromethyl)-1,3,4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation? ACS Pharmacol. Transl. Sci. 2024, February 20.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA